Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DDX3X induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells harboring EGFR-activating mutations.

PloS one - 1 Jan 2014

Nozaki Koichiro, Kagamu Hiroshi, Shoji Satoshi, Igarashi Natsue, Ohtsubo Aya, Okajima Masaaki, Miura Satoru, Watanabe Satoshi, Yoshizawa Hirohisa, Narita Ichiei

Abstract excerpt

The specific mechanisms how lung cancer cells harboring epidermal growth factor receptor (EGFR) activating mutations can survive treatment with EGFR-tyrosine kinase inhibitors (TKIs) until they eventually acquire treatment-resistance genetic mutations are unclear. The phenotypic diversity of canc...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Cell Adhesion
Share to DEAD-box RNA Helicases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Genetic Heterogeneity

Share to Immunoblotting

Share to Neoplastic Stem Cells

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 25343452
DOI: 10.1371/journal.pone.0111019
PMCID: PMC4208809

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25343452-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DDX3X induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells harboring EGFR-activating mutations.PMID 25343452Read ↗

DDX3X mediates EGFR-TKI resistance through VEGFR signalingSemantic proximity Read ↗

The germline factor DDX4 contributes to the chemoresistance of small cell lung cancer cellsSemantic proximity Read ↗

Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment.Semantic proximity Read ↗

MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.Semantic proximity Read ↗

The SOX9-Aldehyde Dehydrogenase Axis Determines Resistance to Chemotherapy in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Primary patient-derived lung adenocarcinoma cell culture challenges the association of cancer stem cells with epithelial-to-mesenchymal transitionSemantic proximity Read ↗

Mutant TP53 promotes invasion of lung cancer cells by regulating desmoglein 3.Semantic proximity Read ↗

TP63 drives TKI resistance in EGFR-mutant lung cancer via ferroptosis inhibition.Semantic proximity Read ↗

Depleting DDX1 sensitizes non-small cell lung cancer cells to chemotherapy by attenuating cancer stem cell traitsSemantic proximity Read ↗

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC.Semantic proximity Read ↗

DDX3X Loss is Associated with Aggressive Phenotypes in Non-Hodgkin’s LymphomasSemantic proximity Read ↗

Cross-talk between SOX2 and TGFβ Signaling Regulates EGFR-TKI Tolerance and Lung Cancer Dissemination.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.